There is evidence for the modulation of synaptic plasticity with pharmacologic, neurostimulation and behavioral treatments [83, 84], however, synaptogenesis promoting interventions specifically targeting SV2A have yet to be established and could represent innovative treatment strategies for psychosis. This evidence concerns the gene SV2A and psychotic disorder.